Search Patents
  • Anti-HCV monoclonal antibody as a medicament for the therapeutic treatment and prevention of HCV infections
    Patent number: 8623363
    Abstract: The present invention relates to the monoclonal antibody e20 or a functional fragment thereof as a medicament for the therapeutic treatment and prevention of HCV infections. The e20 antibody is able to bind all of the known HCV genotypes and exhibits a strong neutralising activity against the virus, in particular towards genotypes 1a, 1b, 2a, and 4. A pharmaceutical composition is also described for the treatment or prevention of HCV infections, which comprises the monoclonal antibody e20 or a functional fragment thereof, and pharmaceutically acceptable excipients, carriers or diluents.
    Type: Grant
    Filed: December 21, 2009
    Date of Patent: January 7, 2014
    Assignee: Pomona Ricerca S.R.L.
    Inventors: Roberto Burioni, Massimo Clementi
  • Human monoclonal antibody Fab fragments directed against HCV E2 glycoprotein and endowed with in vitro neutralizing activity
    Patent number: 7727529
    Abstract: The invention refers to a human antibody, or its functional fragments, directed against the HCV E2 glycoprotein, able to have a neutralizing activity in vivo; a composition for anti-HCV therapy comprising in a therapeutically effective amount the antibody; a composition for topical use in gel, creme, ointment and ovule formulations; the use of the antibody for validating anti-HCV vaccines.
    Type: Grant
    Filed: May 28, 2008
    Date of Patent: June 1, 2010
    Assignee: General Antibodies and Biotechnologies S.R.L
    Inventor: Roberto Burioni
  • Phage display technologies
    Patent number: 7811973
    Abstract: The present invention provides novel technologies for producing and screening fusion proteins on the surface of filamentous phage. In particular, a single vector can be used for generating cell and phage libraries containing a given series of protein sequences fused to either one or other of two phage coat proteins. This approach simplifies and improves the efficiency of the subsequent phage display-based selection of protein-binding molecules having therapeutic or diagnostic utility, such as antibodies, peptides, or epitope-binding regions.
    Type: Grant
    Filed: July 6, 2006
    Date of Patent: October 12, 2010
    Assignee: Ribovax Biotechnologies SA
    Inventors: Roberto Burioni, Massimo Clementi
  • ANTI-HCV MONOCLONAL ANTIBODY AS A MEDICAMENT FOR THE THERAPUTIC TREATMENT AND PREVENTION OF HCV INFECTIONS
    Publication number: 20110256140
    Abstract: The present invention relates to the monoclonal antibody e20 or a functional fragment thereof as a medicament for the therapeutic treatment and prevention of HCV infections. The e20 antibody is able to bind all of the known HCV genotypes and exhibits a strong neutralising activity against the virus, in particular towards genotypes 1a, 1b, 2a, and 4. A pharmaceutical composition is also described for the treatment or prevention of HCV infections, which comprises the monoclonal antibody e20 or a functional fragment thereof, and pharmaceutically acceptable excipients, carriers or diluents.
    Type: Application
    Filed: December 21, 2009
    Publication date: October 20, 2011
    Inventors: Roberto Burioni, Massimo Clememti
  • Ligand capture-directed selection of antibody
    Publication number: 20020168629
    Abstract: The present invention provides a novel method for the identification and clonal isolation of antibodies that bind to unique epitopes. The method is based on the use of antibodies as solid phase capture reagents to bind a known capture antibody epitope, thereby precluding the capture antibody epitope from being presented to a population of antibodies to be screened. The method is particularly suited for screening libraries of cloned antibodies, such as phage display combinatorial antibodies. An antibody specific for herpes simplex virus (HSV), was employed as a model for the assay.
    Type: Application
    Filed: February 19, 2002
    Publication date: November 14, 2002
    Applicant: The Scripps Research Institute, a California Corporation
    Inventors: Dennis R. Burton, Roberto Burioni, R. Anthony Williamson, Pietro P. Sanna
  • Ligand capture-directed selection of antibody
    Patent number: 6376170
    Abstract: The present invention provides a novel method for the identification and clonal isolation of antibodies that bind to unique epitopes. The method is based on the use of antibodies as solid phase capture reagents to bind a known capture antibody epitope, thereby precluding the capture antibody epitope from being presented to a population of antibodies to be screened. The method is particularly suited for screening libraries of cloned antibodies, such as phage display combinatorial antibodies. An antibody specific for herpes simplex virus (HSV), was employed as a model for the assay.
    Type: Grant
    Filed: November 18, 1997
    Date of Patent: April 23, 2002
    Assignee: The Scripps Research Institute
    Inventors: Dennis R. Burton, Roberto Burioni, R. Anthony Williamson, Pietro P. Sanna
  • Antibody for ligand capture assay
    Patent number: 7060799
    Abstract: The present invention provides a novel method for the identification and clonal isolation of antibodies that bind to unique epitopes. The method is based on the use of antibodies as solid phase capture reagents to bind a known capture antibody epitope, thereby precluding the capture antibody epitope from being presented to a population of antibodies to be screened. The method is particularly suited for screening libraries of cloned antibodies, such as phage display combinatorial antibodies. An antibody specific for herpes simplex virus (HSV), was employed as a model for the assay.
    Type: Grant
    Filed: February 19, 2002
    Date of Patent: June 13, 2006
    Assignee: The Scripps Research Institute
    Inventors: Dennis R. Burton, Roberto Burioni, R. Anthony Williamson, Pietro P. Sanna
  • Monoclonal Antibodies Capable of Reacting with a Plurality of Influenza Virus a Subtypes
    Publication number: 20160060325
    Abstract: Monoclonal antibodies directed against the influenza A virus are described, which have the advantageous and unpredicted property of being able to bind a plurality of subtypes of the influenza A virus. One preferred embodiment is the antibody designated as Fab28, which displays a neutralizing activity against a plurality of subtypes of the influenza A virus. Anti-idiotype antibodies directed against the monoclonal antibodies of the invention, immunogenic or vaccine compositions comprising the monoclonal antibodies of the invention are also described, as well as therapeutic, prophylactic and diagnostic applications for the monoclonal antibodies of the invention. The monoclonal antibodies of the invention can also be used for testing antibody preparations to be used as vaccines.
    Type: Application
    Filed: November 11, 2015
    Publication date: March 3, 2016
    Applicant: POMONA RICERCA S.R.L.
    Inventors: Roberto Burioni, Massimo Clementi
  • Monoclonal Antibodies Capable of Reacting with a Plurality of Influenza Virus A Subtypes
    Publication number: 20160200801
    Abstract: Monoclonal antibodies directed against the influenza A virus are described, which have the advantageous and unpredicted property of being able to bind a plurality of subtypes of the influenza A virus. One preferred embodiment is the antibody designated as Fab28, which displays a neutralizing activity against a plurality of subtypes of the influenza A virus. Anti-idiotype antibodies directed against the monoclonal antibodies described herein, immunogenic or vaccine compositions comprising the monoclonal antibodies of the invention are also described, as well as therapeutic, prophylactic and diagnostic applications for the monoclonal antibodies described herein. The monoclonal antibodies can also be used for testing antibody preparations to be used as vaccines.
    Type: Application
    Filed: March 29, 2016
    Publication date: July 14, 2016
    Applicant: Pomona Ricerca S.r.l.
    Inventors: Roberto Burioni, Massimo Clementi
  • Monoclonal antibodies capable of reacting with a plurality of influenza virus A subtypes
    Patent number: 9200063
    Abstract: Monoclonal antibodies directed against the influenza A virus are described, which have the advantageous and unpredicted property of being able to bind a plurality of subtypes of the influenza A virus. One preferred embodiment is the antibody designated as Fab28, which displays a neutralizing activity against a plurality of subtypes of the influenza A virus. Anti-idiotype antibodies directed against the monoclonal antibodies of the invention, immunogenic or vaccine compositions comprising the monoclonal antibodies of the invention are also described, as well as therapeutic, prophylactic and diagnostic applications for the monoclonal antibodies of the invention. The monoclonal antibodies of the invention can also be used for testing antibody preparations to be used as vaccines.
    Type: Grant
    Filed: March 16, 2009
    Date of Patent: December 1, 2015
    Assignee: POMONA RICERCA S.R.L.
    Inventors: Roberto Burioni, Massimo Clementi
  • MONOCLONAL ANTIBODIES CAPABLE OF REACTING WITH A PLURALITY OF INFLUENZA VIRUS A SUBTYPES
    Publication number: 20110014187
    Abstract: Monoclonal antibodies directed against the influenza A virus are described, which have the advantageous and unpredicted property of being able to bind a plurality of subtypes of the influenza A virus. One preferred embodiment is the antibody designated as Fab28, which displays a neutralizing activity against a plurality of subtypes of the influenza A virus. Anti-idiotype antibodies directed against the monoclonal antibodies of the invention, immunogenic or vaccine compositions comprising the monoclonal antibodies of the invention are also described, as well as therapeutic, prophylactic and diagnostic applications for the monoclonal antibodies of the invention. The monoclonal antibodies of the invention can also be used for testing antibody preparations to be used as vaccines.
    Type: Application
    Filed: March 16, 2009
    Publication date: January 20, 2011
    Inventors: Roberto Burioni, Massimo Clementi
  • Monoclonal antibodies capable of reacting with a plurality of influenza virus A subtypes
    Patent number: 9598482
    Abstract: Monoclonal antibodies directed against the influenza A virus are described, which have the advantageous and unpredicted property of being able to bind a plurality of subtypes of the influenza A virus. One preferred embodiment is the antibody designated as Fab28, which displays a neutralizing activity against a plurality of subtypes of the influenza A virus. Anti-idiotype antibodies directed against the monoclonal antibodies described herein, immunogenic or vaccine compositions comprising the monoclonal antibodies of the invention are also described, as well as therapeutic, prophylactic and diagnostic applications for the monoclonal antibodies described herein. The monoclonal antibodies can also be used for testing antibody preparations to be used as vaccines.
    Type: Grant
    Filed: March 29, 2016
    Date of Patent: March 21, 2017
    Assignee: Pomona Ricerca S.r.l.
    Inventors: Roberto Burioni, Massimo Clementi
  • Monoclonal antibodies capable of reacting with a plurality of influenza virus A subtypes
    Patent number: 9587011
    Abstract: Monoclonal antibodies directed against the influenza A virus are described, which have the advantageous and unpredicted property of being able to bind a plurality of subtypes of the influenza A virus. One preferred embodiment is the antibody designated as Fab28, which displays a neutralizing activity against a plurality of subtypes of the influenza A virus. Anti-idiotype antibodies directed against the monoclonal antibodies of the invention, immunogenic or vaccine compositions comprising the monoclonal antibodies of the invention are also described, as well as therapeutic, prophylactic and diagnostic applications for the monoclonal antibodies of the invention. The monoclonal antibodies of the invention can also be used for testing antibody preparations to be used as vaccines.
    Type: Grant
    Filed: November 11, 2015
    Date of Patent: March 7, 2017
    Assignee: Pomona Ricerca S.r.l.
    Inventors: Roberto Burioni, Massimo Clementi
  • MONOCLONAL ANTIBODIES HAVING HOMOSUBTYPE CROSS-NEUTRALIZATION PROPERTIES AGAINST INFLUENZA A VIRUSES SUBTYPE H1
    Publication number: 20110076265
    Abstract: A monoclonal antibody directed against the influenza A virus is described, which is capable of binding human and animal isolates of influenza A viruses expressing the H1-subtype hemagglutinin. A preferred embodiment is the antibody designated as Fab49, which shows a neutralizing activity against a plurality of influenza A virus isolates expressing the H1-subtype hemagglutinin, including animal-derived isolates. Anti-idiotype antibodies directed against the monoclonal antibody of the invention, immunogenic or vaccine compositions comprising the monoclonal antibody of the invention are also described, as well as therapeutic, prophylactic and diagnostic applications for the monoclonal antibody of the invention. The monoclonal antibody of the invention can also be employed for testing antibody preparations to be used as vaccines.
    Type: Application
    Filed: May 27, 2009
    Publication date: March 31, 2011
    Inventors: Roberto Burioni, Massimo Clementi
  • Monoclonal antibodies having homosubtype cross-neutralization properties against influenza A viruses subtype H1
    Patent number: 9243054
    Abstract: A monoclonal antibody directed against the influenza A virus is described, which is capable of binding human and animal isolates of influenza A viruses expressing the H1-subtype hemagglutinin. A preferred embodiment is the antibody designated as Fab49, which shows a neutralizing activity against a plurality of influenza A virus isolates expressing the H1-subtype hemagglutinin, including animal-derived isolates. Anti-idiotype antibodies directed against the monoclonal antibody of the invention, immunogenic or vaccine compositions comprising the monoclonal antibody of the invention are also described, as well as therapeutic, prophylactic and diagnostic applications for the monoclonal antibody of the invention. The monoclonal antibody of the invention can also be employed for testing antibody preparations to be used as vaccines.
    Type: Grant
    Filed: May 27, 2009
    Date of Patent: January 26, 2016
    Assignee: POMONA RICERCA S.R.L.
    Inventors: Roberto Burioni, Massimo Clementi
  • ANTI-IDIOTYPE MONOCLONAL ANTIBODIES AS MIMOTOPES OF THE HIV GP120 ANTIGEN
    Publication number: 20100008905
    Abstract: Novel anti-idiotype monoclonal antibodies are described which are capable of specifically reacting with the idiotype of human anti-gp120 antibodies, of inhibiting the binding between the gp120 antigen and human anti-gp120 antibodies, and of evoking a neutralising anti-gp120 immune response in an animal host to which they are administered. The anti-idiotype antibodies of the invention can be identified based on the amino acid sequences of the variable portions of their light and heavy chains. In addition, a method for obtaining a panel of anti-idiotype monoclonal antibodies, expression vectors and transformed host cells usable in a recombinant DNA procedure in order to generate the aforesaid anti-idiotype monoclonal antibodies, as well as the therapeutic, prophylactic and diagnostic use of such antibodies are disclosed.
    Type: Application
    Filed: January 29, 2008
    Publication date: January 14, 2010
    Inventors: Roberto Burioni, Massimo Clementi
  • Anti-idiotype monoclonal antibodies mimicking the HIV gp120 CD4-binding (CD4bs)
    Patent number: 8367061
    Abstract: Novel anti-idiotype monoclonal antibodies are described which are capable of specifically reacting with the idiotype of human anti-gp120 antibodies, of inhibiting the binding between the gp120 antigen and human anti-gp120 antibodies, and of evoking a neutralising anti-gp120 immune response in an animal host to which they are administered. The anti-idiotype antibodies of the invention can be identified based on the amino acid sequences of the variable portions of their light and heavy chains. In addition, a method for obtaining a panel of anti-idiotype monoclonal antibodies, expression vectors and transformed host cells usable in a recombinant DNA procedure in order to generate the aforesaid anti-idiotype monoclonal antibodies, as well as the therapeutic, prophylactic and diagnostic use of such antibodies are disclosed.
    Type: Grant
    Filed: January 29, 2008
    Date of Patent: February 5, 2013
    Assignee: Pomona Ricera S.R.L.
    Inventors: Roberto Burioni, Massimo Clementi
  • Human Antibodies Cross-Reacting With A Bacterial And A Self Antigen From Atherosclerotic Plaques
    Publication number: 20120165211
    Abstract: The present invention refers to human antibodies derived from human antibody libraries prepared from atherosclerotic plaques. It further refers to human antibodies able to immunologically recognize both human transgelin or fragments thereof and a protein with at least 50% similarity to OmpK36 (Outer membrane protein, Klebsiella, K36; GI: 295881594) or fragments thereof. Human transgelin is preferably transgelin 1 (Accession N° Q01995, GI:48255907). The antibodies further recognize an antigen in the atherosclerotic plaque and are useful for the preparation of immunodiagnostic reagents or assays to detect atherogenic diseases. The invention also relates to the use of anti-TAGLN monoclonal antibodies, showing cross-reactivity with a bacterial antigen having at least 50% similarity with OmpK36, for detecting antigens in the atherosclerotic plaque or as atherosclerotic related reagents in an immuno-competition assay.
    Type: Application
    Filed: January 13, 2012
    Publication date: June 28, 2012
    Applicant: BRACCO IMAGING S.P.A.
    Inventors: Roberto BURIONI, Filippo CANDUCCI, Massimo CLEMENTI, Federico MAISANO
  • Method for identifying the proteome of cells using an antibody library microarray
    Publication number: 20050130320
    Abstract: The invention describes a method for identifying the level of various proteins in a cells or tissue and also comparing the levels of the same protein in two different tissues which we have termed as Antibody Microarray Proteomics Technology (AMP Technology). Proteins that are differentially expressed between a normal and disease tissue could be involved in the disease process and disease tissue could be involved in the disease process and hereby makes it a potential drug or diagnostic target. AMP technology makes use of the method of phage display selection or similar combinatorial antibody selection techniques to select antibodies to a given protein. Antibodies to all of most proteins present in the diseased and normal tissue are produced in an appropriate animal (mice) and mRNA encoding antibodies are isolated, cloned into filamentous phage (or bacteria or yeast) vectors such that the antibodies are expressed as a fusion with the phage filaments.
    Type: Application
    Filed: November 8, 2001
    Publication date: June 16, 2005
    Inventors: Shaji. George, Roberto Burioni
Narrow Results

Filter by US Classification